Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy
Takeda Pharmaceutical Company Limited (TAK) announced promising interim results from its Phase 1b trial of mezagitamab (TAK-079) for IgA nephropathy. The study showed stable kidney function, measured by estimated glomerular filtration rate (eGFR), maintained through Week 96, up to 18 months post-treatment. These findings were presented at the ASN Kidney Week 2025 in Houston. IgA nephropathy is a progressive autoimmune disease affecting young individuals, with no current cure and a significant risk of renal failure.
Takeda Pharmaceutical Company Limited (TAK) announced new interim findings from its Phase 1b open-label proof-of-concept trial evaluating subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with primary immunoglobulin A (IgA) nephropathy.
The data revealed that kidney function, measured by estimated glomerular filtration rate (eGFR), remained stable through Week 96—up to 18 months after the final dose of mezagitamab. These results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston.
IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
